Benzinga | Aug 5, 2021 06:00PM EDT

Nektar Therapeutics Q2 EPS $(0.69) Beats $(0.74) Estimate, Sales $28.33M Beat $25.98M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.74) by 6.76 percent. This is a 53.33 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $28.33 million which beat the analyst consensus estimate of $25.98 million by 9.05 percent. This is a 42.00 percent decrease over sales of $48.85 million the same period last year.